Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

January 3, 2003

Study Completion Date

January 3, 2003

Conditions
Acromegaly
Interventions
DRUG

Lanreotide (Autogel formulation)

Trial Locations (29)

1088

Semmelweiss University Medical School, Budapest

1135

Semmelweiss University, Budapest

2300

Academic Hospital Leiden, Leiden

3000

Academic Hospital Rotterdam, Rotterdam

10010

New York University Medical Center, New York

10117

Universitätklinikum Charité, Berlin

19104

University of Pennsylvania, Philadelphia

21287

Johns Hopkins University School of Medicine, Baltimore

35213

Baptist Health System Inc, Birmingham

45147

Med. Klinik der Universitätat Essen, Essen

45267

University of Cincinnati, Cincinnati

48109

University of Michigan Medical Center, Ann Arbor

54511

CHRU de Brabois, Vandœuvre-lès-Nancy

59037

Clinique Marc Linquette, Lille

60611

Northwestern Medical Facility, Chicago

75010

Hôpital Lariboisière - Service de Médecine B, Paris

75014

Hôpital Cochin - Service d'Endocrinologie, Paris

77030

Ben Taub Hospital, Houston

80336

Medizinische Klinik Innenstadt, München

90048

Pituitary Center, Los Angeles

97201

Oregon Health Sciences University, Portland

02114

Massachusetts General Hospital, Boston

Unknown

St Ann's Faculty Hospital, Brno

Queen Mary Hospital, Pokfulam

500 05

University Hospital Charles University, Hradec Králové

120 00

Charles University, Prague

B15 2TH

Queen Elizabeth Hospital, Edgbaston

NW3 2QG

The Royal Free Hospital, Hampstead

M204BX

Christie Hospital, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY